Benchmark：重申Humacyte(HUMA.US)评级，由买入调整至买入评级,目标价由15.00美元调整至15.00美元。
Humacyte(HUMA.US)公司简介：Humacyte Inc正在开发一个颠覆性的生物技术平台，以提供可普遍植入的生物工程人体组织和器官，旨在改善患者的生活并改变医学实践。它开发和制造用于治疗各种疾病、损伤和慢性病的脱细胞组织。
Benchmark：重申Humacyte(HUMA.US)评级
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.